



Bladder Cancer Studies

DN24-02 (vaccination)

DN24-02 (vaccination) added to standard of care treatment for patients with HER2+ bladder cancer **Recruiting**

Avastin added to Gemcitabine + Cisplatin chemotherapy

Phase II study comparing Avastin, Gemcitabine + Cisplatin chemotherapy to Gemcitabine + Cisplatin alone **Recruiting**

Intravesical chemotherapy with Gemcitabine, Mitomycin Taxotere

Treatment for superficial bladder cancer in which chemotherapy drugs are infused directly into the bladder through a catheter (intravesical) **Recruiting**

Bladder preservation

Bladder preservation with chemotherapy prior to surgery, TURBT (transurethral resection of bladder tumor), concurrent radiation + chemotherapy **Recruiting**

STUDIES ACTIVE, CLOSED TO ENROLLMENT

OGX-427-02 added to Gemcitabine + Cisplatin chemotherapy

Phase II study of Gemcitabine + Cisplatin chemotherapy with study drug OGX-427-02 for advanced bladder cancer **Closed to enrollment – active follow-up**